Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

merck

Home/Tag:merck
2 01, 2016

The power of combination therapies

Tags: , , , |4 Comments

New checkpoint inhibitor studies combining the experimental drug, Keytruda, with Revlimid, are working in patients who have become refractory to Revlimid. I found this great article on Linkedin.com on Saturday. I didn't even know there was such a thing. I thought that Linkedin was a professional job networking site. Apparently, professionals in healthcare can post

22 12, 2015

Hopeful news about first PD-1 inhibitor

Tags: , , , |2 Comments

Another exciting, new immunotherapy may be on the horizon: Keytruda In meetings of well informed patient activists and experts after ASH, several in the group were excited about a new class of drug called PD-1 inhibitors. Jenny Ahlstrom was practically doing back flips over it. Here's info on the first of let's hope are several

17 10, 2010

Some Good News About Vorinostat: Oncologists Can Use It "Off Label" In Multiple Myeloma Patients

Tags: , , , , , |0 Comments

I would like to take this opportunity to once again thank Dr. Eric Rubin, Vice President of Merck Oncology, for taking the time to update us on vorinostat's projected timeline.You may have noticed quite a bit of hedging and "drug company speak" toward the end of our interview.  I want to point out that Dr. Rubin wasn't intentionally

16 10, 2010

Part Two Of A Two Part Interview With Merck Oncology’s Vice President, Dr. Eric Rubin, About New Anti-Multiple Myeloma Drug, Vorinostat

Tags: , , , , |0 Comments

Here is the second part of my two part interview with Dr. Eric Rubin, Vice President of Merck Oncology, makers of vorinostat--trade name Zolinza:My understanding is, like many anti-myeloma agents, Zolinza is most effective when combined with other novel therapy agents. Which combinations show the most promise thus far? Why do you think that is?All

15 10, 2010

Part One Of A Two Part Interview With Merck Oncology’s Vice President, Dr. Eric Rubin, About New Anti-Multiple Myeloma Drug, Vorinostat

Tags: , , , , , , , |0 Comments

I have written a lot about two developmental, anti-myeloma drugs here recently, carfilzomib and pomalidomide.  But there are a number of other new, experimental drugs on the horizon.One of these, vorinostat, looks expecially promising.  Vorinostat is being developed by Merck Oncology.  Vorinostat doesn't do much to fight multiple myeloma on it's own.  But early combination

17 02, 2010

Multiple Myeloma Drug, Vorinostat, Phase II Trial To Move Forward

Tags: , , , , |0 Comments

Here is a press release, posted on the Drug Discovery & Development Website from Merck Pharmaceuticals about the new, experimental multiple myeloma drug, Vorinostat:Board Recommends Continuation of Phase IIb Study of VorinostatDrug Discovery & Development - February 15, 2010Merck & Co., Inc. announced that an independent Data Safety and Monitoring Board recommended the continuation of